Randomized Studies Inappropriate For Uterine Fibroid Treatment - FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Randomized, controlled clinical trials are both impractical and ill-advised to determine the safety and efficacy of non-extirpative methods of treating uterine fibroids, FDA's Obstetrics and Gynecology Devices Panel agreed Oct. 4.
You may also be interested in...
Cryomyolysis
Procedure to treat uterine fibroids uses a catheter cooled to -110degrees C prior to insertion into the fibroid for five to ten minutes, not 110degrees as was reported by "The Gray Sheet" (1Oct. 11, p. 12)
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.